Contents of volume 27

No. 1 (pp 1- 80) published 23 October 1990
No. 2 (pp 81-170) published 22 November 1990
No. 3 (pp 171-252) published 14 December 1990
No. 4 (pp 253-334) published 28 January 1991
No. 5 (pp 335-416) published 25 February 1991
No. 6 (pp 417-492) published 27 March 1991

Aakvaag A → Lundgren S
Abbruzzese JL → Grunewald R
Achterrath W → Eiermann W
Ahn DK → Gandara DR
Aisner J → Vogelzang NJ
Akaza H → Kotake T
Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher RI: Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model 33
Ambroso G → Strocchi E
Ames FC → Koh EH
Anthony LB, Long Q-C, Struck RF, Hande KR: The effect of cimetidine on cyclophosphamide metabolism in rabbits 125
Arakali AV → Pendyala L
Arcaute V → Avril M-F
Arentsen-Honders W → Colly LP
Asade RH, Prizont L, Muiño JP, Tessler J: Steady-state hydroxyflutamide plasma levels after the administration of two dosage forms of flutamide 401
Asami N → Tsuruo T
Ash CM → Twelves CJ
Atassi G → El Abed I
Avril M-F, Bonneterre J, Delaunay M, Grosshans E, Fumoleau P, Israel L, Bugat R, Namer M, Cupissol D, Kerbrat P, Montcuquet P, Arcaute V, Bizzari J-P: Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group 81

Bach F → Sørensen JB
Baker LH → Chabot GG
Balch CM → Koh EH
Balli M → Strocchi E
Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD: Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes 13
Bartelink H → Deurloo MJ
Bartelink H → Deurloo MJM
Bayliss EJ → O'Brien MER
Becher R → Beelen DW
Beelen DW, Schilcher RB, Ehrlich R, Quabeck K, Schmidt U, Szy D, Grosse-Wilde H, Becher R, Schaefer UW: High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study 361
Begg AC → Nagel JD
Begg AC → Deurloo MJ
Begg AC → Deurloo MJM
Berendsen HH → Postmus PE
Berger DP → Schwendener RA
Berger MP → Schwendener RA
Bichisao E → Strocchi E
Bigner DD → Wang AM
Bizzari J-P → Avril M-F
Blake P → Coleman RE
Blois M-C de → Lejeune J
Bodell WJ → Wang AM
Bohlken S → Deurloo MJ
Bonciarelli G → Strocchi E
Bonneterre J → Avril M-F
Borsi JD, Sagen E, Romslo I, Slørdal L, Moe PJ: 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia 164
Bosl GJ → Motzer RJ
Bouffard DY → Momparler RL
Bourrier M → Jacquet J-M
Breen M → Ings RMJ
Bres J → Pujol J-L
Bressolle F → Jacquet J-M
Briggs M → Ings RMJ
Brodfuehrer J, Valeriote F, Chan K, Heilbrun L, Corbett T: Flavone acetic acid and plasma protein binding 27
Brookes P, Venitt S: Obituary for John J. Roberts 333
Bugat R → Avril M-F
Buzdar AU → Koh EH

Caggiano V → Gandara DR
Calman F → Coleman RE
Camaggi CM → Strocchi E
Campbell DB → Ings RMJ
Campling D → Robbins MEC
Cantoni O, Sestili P, Cattabeni F, Geroni C, Giuliani F: Comparative effects of doxorubicin and 4′-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line 47
Carfagna PF, Poma A, Wyrick SD, Holbrook DJ, Chaney SG: Comparisons of tetrachloro (d,l-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses 335
Carlson RW → Gandara DR
Carmo-Pereira J, Costa FO, Miles DW, Henriques E, Richards MA, Rubens RD: High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study 394
Cattabeni F → Cantoni O
Cawley JC → Phillips JK
Cellerino R → Strocchi E
Chabot GG, Flaherty LE, Valdivieso M, Baker LH: Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients 157
Chaitchik S → Merimsky O
Chaney SG → Carfagna PF
Chan K → Brodfuehrer J
Chan TK → Liang R
Chapman DE, Powis G: Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2′,3′-dideoxyadenosine 285
Chauvel P → Milano G
Chiu E → Liang R
Choy D → Liang R
Clarke JM → Coleman RE
Colemann RE, Clarke JM, Slevin ML, Sweetenham J, Williams CJ, Blake P, Calman F, Wiltshaw E, Harper PG: A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix 52
Colly LP, Richel DJ, Arentsen-Honders W, Starrenburg IWJ, Edelbroek PM, Willemze R: A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells 151
Comis RL → O'Dwyer PJ
Conti G → Di Carlo F
Coombes RC → Jones AL
Coombes RC → Haynes BP
Cooper MR → Vogelzang NJ
Corbett T → Brodfuehrer J
Cornfeld MJ → O'Dwyer PJ
Corson JM → Vogelzang NJ
Costa FO → Carmo-Pereira J
Coughlin KM → Vogelzang NJ
Cowens JW → Pendyala L
Creaven PJ → Pendyala L
Crowther D → McGown AT
Cullis PR → Bally MB
Cupissol D → Pujol J-L
Cupissol D → Avril M-F

Dadoun C, Raguenez-Viotte G: Celiptium-induced nephrotoxicity and lipid peroxidation in rat cenal cortex 178
Danon A → Merimsky O
David M → Robert J
Davies J → Junor E
Davies JM → Phillips JK
Dekker H → Spoelstra EC
Delaunay M → Avril M-F
Deurloo MJ, Bohlken S, Kop W, Lerk CF, Hennink W, Bartelink H, Begg AC: Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity 135
Deurloo MJM, Kop W, van Tellingen O, Bartelink H, Begg AC: Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution 347
Deutsch J → Genka S
Devereux K → Ings RMJ
Di Carlo F, Conti G, Giubertoni M, Muccioli G, Racca S: Potentiation of medroxyprogesterone acetate antineoplastic activity by histidine in rat mammary tumours 271
Dittrich C → Mader RM
Dombernowsky P → Sørensen JB
Donadio D → Jacquet J-M

Dorr RT, Liddil JD: Modulation of mitomycin C-induced multidrug resistance in vitro 290
Dowsett M, Lloyd P: Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men 67
Dowsett M → Haynes BP
Dunkelman H, Earl HM, Twelves C: Acute reversible neurological deficit following intrathecal chemotherapy 329
Dusleag J → Samonigg H

Earl HM → Dunkelman H
Edelbroek PM → Colly LP
Edwards FE → Ings RMJ
Eguchi K → Sasaki Y
Ehrlich R → Beelen DW
Eiermann W, Achterrath W, Lenaz L, Hepp H: Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study 389
El Abed I, Roger P, Gosse C, Atassi G, Gouyette A: Chemical stability of ecomustine, a new antitumor agent in aqueous and biological media as assessed by high-performance liquid chromatography 295
Elion GB → Wang AM
Erickson LC → Albain KS
Evans WE → Petros WP

Fiebig HH → Schwendener RA
Fischer D → Merimsky O
Fisher RI → Albain KS
Fitzsimmons WE, Ghalie R, Kaizer H: The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity 226
Flaherty LE → Chabot GG
Flombaum C → Motzer RJ
Fontana CX → Milano G
Forgeson GV → Jones AL
Foth H → Rauschecker HF
Fox BW → McGown AT
Fraschini G → Koh EH
French BT, Patrick DE, Grever MR, Trewyn RW: Differential effect of 6-ethylmercaptopurine on c-myc expression in wild-type and HGPRT-deficient HL-60 cells 171
Friche E → Jensen PB
Friedman HS → Wang AM
Frühauf S, Zeller WJ: In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors 301
Frye D → Koh EH
Fujiwara K → Saita T
Fumoleau P → Avril M-F

Galtier M → Jacquet J-M
Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW: High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group 243
Gatzemeier W → Rauschecker HF
Genka S, Deutsch J, Stahle PL, Shetty UH, John V, Robinson C, Rapoport SI, Greig NH: Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat 1
Geroni C → Cantoni O
Gescher A → Tsang LLH
Gestin-Boyer C → Pujol J-L
Ghalie R → Fitzsimmons WE
Gilbert KS → Waud WR
Giubertoni M → Di Carlo F
Giuliani F → Cantoni O
Glüsenkamp K-H → Jähde E
Gosse C → El Abed I
Goutsou M → Vogelzang NJ
Gouyette A → El Abed I
Granger C → Robert J
Gray AJ → Ings RMJ
Graziano S → Vogelzang NJ
Green MR → Vogelzang NJ
Green RM → Stewart DJ
Greig NH → Genka S
Grever MR → French BT
Grewaal D → Stewart DJ
Griggs LJ → Haynes BP
Griswold DP Jr → Waud WR
Grosse-Wilde H → Beelen DW
Grosshans E → Avril M-F
Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W: Saturation of 2′,2′difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine 258
Gupta S → Stewart DJ

Habeshaw T → Junor E
Haegele KD → Logue J
Hagen B: Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects 373
Hande KR → Anthony LB
Hansen HH → Jensen PB
Hansen HH → Sørensen JB
Harper PG → Coleman RE
Harris MB → Newman EM
Harrison SD Jr → Waud WR
Hasle H: Cerebellar toxicity during cytarabine therapy associated with renal insufficiency 76
Hayashi K → Takemura Y
Hay CRM → Phillips JK
Haynes BP, Jarman M, Dowsett M, Mehta A, Lønning PE, Griggs LJ, Jones A, Powles T, Stein R, Coombes RC: Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer 367
Heilbrun L → Brodfuehrer J
Heinonen E → Liippo K
Hennink W → Deurloo MJ
Henriques E → Carmo-Pereira J
Hepp H → Eiermann W
Holbrook DJ → Carfagna PF
Holmes FA → Koh EH
Hopewell JW → Robbins MEC
Horst F → Rauschecker HF
Hortobagyi GN → Koh EH
Hug V → Koh EH

Inaba M → Mitsuhashi Y
Inaba M → Tsuruo T
Indelli M → Strocchi E
Ings RMJ, Breen M, Devereux K, Gray AJ, Edwards FE, Lucas C, Briggs M, Robinson BV, Campbell DB: The comparative disposition of [^{14}C]-fotemustine in non-tumourous and tumourous mice 106
Isaacs M → Motzer RJ
Israel L → Avril M-F
Israel M → Sweatman TW

Jäckel M, Köpf-Maier P: Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas 464
Jackson GH, Wallis J, Ledingham J, Lennard A, Proctor SJ: Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia 168
Jacquet J-M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi J-F: Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters 219
Jähde E, Glüsenkamp K-H, Rajewsky MF: Nigericin enhances mafosfamide cytotoxicity at low extracellular pH 440
Jarman M → Haynes BP
Jensen PB, Roed H, Skovsgaard T, Friche E, Vindeløv L, Hansen HH, Spang-Thomsen M: Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation 194
John V → Genka S
Jones A → Haynes BP
Jones AL, Powles TJ, Forgeson GV, Coombes RC: A clinical study of nafazatrom in advanced human breast cancer 326
Jourdan J → Jacquet J-M
Junor E, Davies J, Habeshaw T, Kaye S, Paul J, Rankin E, Reed N, Symonds RP: Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix 484

Kahl GF → Rauschecker HF
Kaizer H → Fitzsimmons WE
Kangas L: Biochemical and pharmacological effects of toremifene metabolites 8
Kasparek A-K → Samonigg H
Kawachi H → Saito H
Kaye S → Junor E
Kerbrat P → Avril M-F
Kitagawa T → Saita T
Kobayashi H → Takemura Y
Kobayashi T → Mitsuhashi Y
Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Homes FA, Fraschini G, Hug V, Theriault RL, Balch CM, Hortobagyi GN: Inflammatory carcinoma of the breast: results of a combined-modality approach

– M. D. Anderson Cancer Center expedrience 94
Kolarić K, Vukas D: Carboplatin activity in untreated metastatic breast cancer patients – results of a phase II study 409
Köpf-Maier P → Jäckel M
Kop W → Deurloo MJ
Kop W → Deurloo MJM
Kotake T, Miki T: Combination salvage chemotherapy using cisplatin and teniposide for patients with refractory germinal testicular tumors 85
Kotake T, Miki T, Akaza H, Kubota Y, Nishio Y, Matsumura Y, Ota K, Ogawa N: Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer 253
Krance RA → Newman EM
Krenmayr P → Mader RM
Kubota Y → Kotake T
Kvinnsland S → Lundgren S

Lagrange JL → Milano G
Lankelma J → Spoelstra EC
Laskin JD → Yurkow EJ
Lassiani L → Sava G
Laster R Jr → Waud WR
Lechner P → Samonigg H
Ledingham J → Jackson GH
Leeuwenkamp OR, van der Vijgh WJf, Neijt JP, Pinedo HM: Reaction kinetics of cisplatin and its monoacquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP 111
Lejeune J, Peeters M, Rethore M-O, Blois M-C de: Homocysteine and the methotrexate toxicity in trisomy 21 331
Lenaz L → Eiermann W
Lennard A → Jackson GH
Leonard RCF → O'Brien MER
Lerk CF → Deurloo MJ
Liang R, Chiu E, Todd D, Chan TK, Choy D, Loke SL: Chemotherapy for early-stage gastrointestinal lymphoma 385
Li D-D → Xu Y-J
Liddil JD → Dorr RT
Liippo K, Nikkanen V, Heinonen E: Carboplatin and etoposide in advanced lung cancer: – a phase I study 229
Lloyd P → Dowsett M
Logue J, Wilkinson P, Haegele KD, Orwin J: A single-dose-finding study of the antiemetic effect and associated plasma levels of MDL 72222 in patients receiving cisplatin 472
Loke SL → Liang R
Long Q-C → Anthony LB
Lønning PE → Lundgren S
Lønning PE → Haynes BP
Los G → Nagel JD
Lucas C → Ings RMJ
Lundgren S, Lønning PE, Aakvaag A, Kvinnsland S: Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer 101

Mader RM, Steger GG, Moser K, Rainer H, Krenmayr P, Dittrich C: Instability of the anticancer agent etoposide under in vitro culture conditions 354
Malacarne P → Strocchi E
Malec M → Gandara DR
Maroun JA → Stewart DJ
Martoni A → Strocchi E
Masin D → Bally MB
Masuda H → Nakajima T
Matsumura Y → Kotake T
Mayer LD → Bally MB
McGown AT, Murphy D, Crowther D, Fox BW: Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy 413
McNeese MD → Koh EH
McVie JG → Nagel JD
Mehta A → Haynes BP
Menendez-Botet C → Motzer RJ
Merimsky O, Rubinstein M, Fischer D, Danon A, Chaitchik S: Pharmacokinetics of recombinant interferon alpha-C 406
Meyers F → Gandara DR
Michaelis HC → Rauschecker HF
Michalowski A → Robbins MEC
Michel F-B → Pujol J-L
Miki T → Kotake T
Miki T → Kotake T
Milano G, Troger V, Fontana CX, Chauvel P, Lagrange JL: Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser 55
Miles DW → Carmo-Pereira J
Miles DW → Twelves CJ
Mirro J Jr. → Petros WP
Miseria S → Strocchi E
Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura KI, Tanaka M, Nishimura T, Inaba M, Kobayashi T: Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up 20
Miyachi H → Takemura Y
Moe PJ → Borsi JD
Momparler LF → Momparler RL
Momparler RL, Onetto-Pothier N, Bouffard DY, Momparler LF: Cellular pharmacology of 1-β-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells 141
Montcuquet P → Avril M-F
Morgan SA → Smith PJ
Mori M → Saita T
Morimoto M → Tsuruo T
Moser K → Mader RM
Motzer RJ, Niedzwiecki D, Isaacs M, Menendez-Botet C, Tong WP, Flombaum C, Scher HI, Bosl GJ: Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency 234
Muccioli G → Di Carlo F
Muiño JP → Asade RH
Murphy D → McGown AT

Nagel JD, Los G, Begg AC, McVie JG: A new intraperitoneal tumor model in the rat 121
Nakajima T, Okamoto T, Masuda H, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T: Mechanism of tumor cell killing by HO-221, a novel antitumor compound 199
Nakamura KI → Mitsuhashi Y
Namer M → Avril M-F
Nash JR → Phillips JK
Nayar R → Bally MB
Newman EM, Villacorte DG, Testi AM, Krance RA, Harris MB, Ravindranath Y, Pinkel D: Biochemical interactions between methotrexate and 1-β-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study 60
Niedzwiecki → Motzer RJ
Nijt JP → Leeuwenkamp OR
Nikkanen V → Liippo K
Nishimura T → Mitsuhashi Y
Nishio Y → Kotake T
Nisi C → Sava G
Nitanai T → Mitsuhashi Y

O'Brien MER, Bayliss EJ, Stewart ME, Smyth JF, Rodger A, Leonard RCF: A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer 79
O'Dwyer PJ, Cornfeld MJ, Peter R, Comis RL: Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination 131
Ogawa N → Kotake T
Ohe Y → Sasaki Y
Ohmori T → Sasaki Y
Ohnuma T → Takemura Y
Okamoto T → Nakajima T
Onetto-Pothier N → Momparler RL
Orwin J → Logue J
Ota K → Kotake T
Ozawa S → Mitsuhashi Y

Pacor S → Sava G
Pannuti F → Strocchi E
Pan S-S: Porfiromycin disposition in oxygen-modulated P388 cellls 187
Parry H → Phillips JK
Patrick DE → French BT
Paul J → Junor E
Peeters M → Lejeune J
Pendyala L, Arakali AV, Sansone P, Cowens JW, Creaven PJ: DNA binding of iproplatin and its divalent metabolite *cis*-dichloro-*bis*-isopropylamine platinum (II) 248
Perez EA → Gandara DR
Perissin L → Sava G
Peter R → O'Dwyer PJ
Peters GJ → Spoelstra EC
Petros WP, Rodman JH, Mirro J Jr., Evans WE: Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia 397

Pfeiffer K → Samonigg H
Phillips JK, Spearing RL, Davies JM, Hay CRM, Parry H, Nash JR, Cawley JC: VIM-D salvage chemotherapy in Hodgkin's disease 161
Pinedo HM → Leeuwenkamp OR
Pinedo HM → Spoelstra EC
Pinkel D → Newman EM
Plunkett W → Grunewald R
Poma A → Carfagna PF
Postmus PE, Smit EF, Berendsen HH, Sleyfer DT: A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status 490
Powis G → Chapman DE
Powles T → Haynes BP
Powles TJ → Jones AL
Prizont L → Asade RH
Proctor SJ → Jackson GH
Pujol J-L, Cupissol D, Gestin-Boyer C, Bres J, Serrou B, Michel F-B: Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small lung cancer patients 72

Quabeck K → Beelen DW
Quarterman CP → Tsang LLH

Racca S → Di Carlo F
Raguenez-Viotte G → Dadoun C
Rainer H → Mader RM
Rajewsky MF → Jähde E
Rankin E → Junor E
Rapoport SI → Genka S
Rauschecker HF, Foth H, Michaelis HC, Horst F, Gatzemeier W, Willenbrock C, Voth E, Kahl GF: Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb 379
Ravindranath Y → Newman EM
Redmond D → Stewart DJ
Reed N → Junor E
Rethore M-O → Lejeune J
Richards MA → Carmo-Pereira J
Richel DJ → Colly LP
Robbins MEC, Campling D, Whitehouse E, Hopewell JW, Michalowski A: Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig 211
Robert J, David M, Granger C: Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug 147
Robillard L → Stewart DJ
Robinson BV → Ings RMJ
Robinson C → Genka S
Robustelli Della Cuna G → Strocchi E
Rodger A → O'Brien MER
Rodman JH → Petros WP
Roed HJ → Jensen PB
Roger P → El Abed I
Romslo I → Borsi JD
Rossi J-F → Jacquet J-M
Rubens RD → Carmo-Pereira J
Rubinstein M → Merimsky O

Sagen E → Borsi JD
Saijo N → Sasaki Y
Saita T, Fujiwara K, Kitagawa T, Mori M, Takata K: A highly sensitive enzyme-linked immunosorbent assay for etoposide using β-D-galactosidase as a label 115
Saito H, Shimokata K, Yamamoto M, Saka H, Sakai S, Kawachi H, Saito H: Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer 251
Saito H → Saito H
Saka H → Saito H
Sakai S → Saito H
Samonigg H, Stöger H, Kasparek A-K, Schmid M, Dusleag J, Pfeiffer K, Smola M, Steindorfer P, Lechner P: Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer 477
Sansone P → Pendyala L
Sasahara K → Mitsuhashi Y
Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N: Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay 263
Sava G, Zorzet S, Perissin L, Pacor S, Lassiani L, Nisi C, Varnavas A: Antineoplastic action of *p*-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK 423
Schaefer UW → Beelen DW
Scher HI → Motzer RJ
Schilcher RB → Beelen DW
Schmid M → Samonigg H
Schmidt U → Beelen DW
Schold SC Jr → Wang AM
Schwendener RA, Fiebig HH, Berger MR, Berger DP: Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy 429
Sekiguchi S → Takemura Y
Serrou B → Pujol J-L
Seshadri R → Sweatman TW
Sestili P → Cantoni O
Shetty UH → Genka S
Shimokata K → Saito H
Shinkai T → Sasaki Y
Singletary SE → Koh EH
Skovsgaard T → Jensen PB
Slack JA → Tsang LLH
Slevin ML → Coleman RE
Sleyfer DT → Postmus PE
Slørdal L → Borsi JD
Smit EF → Postmus PE
Smith PJ, Morgan SA, Watson JV: Detection of multidrug resistance and quantification of response of human tumour cells to cytotoxic agents using flow cytometric spectral shift analysis of Hoechst 33342-DNA fluorescence 445
Smola M → Samonigg H
Smyth JF → O'Brien MER
Sørensen JB, Bach F, Dombernowsky P, Hansen HH: Phase II study of teniposide in adenocarcinoma of the lung 487
Souhami RL → Twelves CJ
Spang-Thomsen M → Jensen PB
Spearing RL → Phillips JK
Spoelstra EC, Pinedo HM, Dekker H, Peters GJ, Lankelma J: Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system 320
Stahle PL → Genka S
Starrenburg IWJ → Colly LP
Steger GG → Mader RM
Steindorfer P → Samonigg H
Stein R → Haynes BP
Stewart DJ, Grewaal D, Green RM, Verma S, Maroun JA, Redmond D, Robillard L, Gupta S: Bioavailability and pharmacology of oral idarubicin 308
Stewart ME → O'Brien MER
Stiff PJ → Albain KS
Stöger H → Samonigg H
Strocchi E, Camaggi CM, Martoni A, Cellerino R, Miseria S, Malacarne P, Indelli M, Balli M, Bonciarelli G, Ambroso G, Bichisao E, Robustelli Della Cuna G, Pannuti F: Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses 451
Struck RF → Anthony LB
Sudo Y → Tsuruo T
Sugiyama Y → Mitsuhashi Y
Suzuki Y → Vogelzang NJ
Sweatman TW, Seshadri R, Israel M: Metabolism and elimination of rhodamine 123 in the rat 205
Sweetenham J → Coleman RE
Swinnen LJ → Albain KS
Symonds RP → Junor E
Szy D → Beelen DW

Taguchi T → Nakajima T
Takata K → Saita T
Takemura Y, Kobayashi H, Miyachi H, Hayashi K, Sekiguchi S, Ohnuma T: The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro 417
Tamura T → Sasaki Y
Tanaka M → Mitsuhashi Y
Tarassoff P → Grunewald R
Tessler J → Asade RH
Testi AM → Newman EM
Theriault RL → Koh EH
Thomas DGT → Twelves CJ
Todd D → Liang R
Tong WP → Motzer RJ
Trewyn RW → French BT
Troger V → Milano G
Tsang LLH, Quarterman CP, Gescher A, Slack JA: Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide 342
Tsukagoshi S → Nakajima T
Tsuruo T, Sudo Y, Asami N, Inaba M, Morimoto M: Antitumor activity of a derivative of mitomycin, 7-*N*-[2-[[2-(γ-L-glutamylamine)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human

tumors and a mitomycin C-resistant tumor in vitro and in vivo 89
Twelves C → Dunkelman H
Twelves CJ, Ash CM, Miles DW, Thomas DGT, Souhami RL: Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma 481

Valdivieso M → Chabot GG
Valeriote F → Brodfuehrer J
van der Vijgh WJf → Leeuwenkamp OR
van Tellingen O → Deurloo MJM
Varnavas A → Sava G
Verma S → Stewart DJ
Venitt S → Brookes P
Villacorte DG → Newman EM
Vindeløv L → Jensen PB
Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J, Cooper MR, Coughlin KM, Green MR: Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B 239

Voth E → Rauschecker HF
Vukas D → Kolarić K

Wallis J → Jackson GH
Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC Jr: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts 278
Watanabe M → Nakajima T
Watson JV → Smith PJ
Waud WR, Harrison SD Jr, Gilbert KS, Laster R Jr, Griswold DP Jr: Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia 456
Whitehouse E → Robbins MEC
Wilkinson P → Logue J
Willemze R → Colly LP
Willenbrock C → Rauschecker HF
Williams CJ → Coleman RE
Wiltshaw E → Coleman RE
Wold H → Gandara DR
Wyrick SD → Carfagna PF

Xu Y-J, Li D-D, Zhen Y-S: Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells 41

Yamada N → Nakajima T
Yamamoto M → Saito H
Yokoyama K → Nakajima T
Yurkow EJ, Laskin JD: Mechanism of action of psoralens: isobologram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic 315

Zeller WJ → Frühauf S
Zhen Y-S → Xu Y-J
Zorzet S → Sava G

Indexed in *Current Contents*

Subject index of volume 27

Adenocarcinoma 487
Adriamycin 413
Advanced breast cancer 101, 394, 477
Advanced human breast cancer 326
Advanced lung cancer 229
Advanced non-small cell lung cancer 243
Alkylating drugs 278
Alveolitis 168
Aminoglutethimide 101, 451
Amsacrine 397
Animal scale-up 20
Anthracycline metabolism 147
Antiemetic effect 472
Antiestrogens 8
Antimetastatic compound 423
Antitumor activity 89, 194, 263
Antitumor agent 295
Antitumor biotic 41
Antitumor effects 8, 429
Ara-C 151
Aromatase inhibitor 367

Bioavailability 308
Biochemical modulation 60
Biodistribution 13
Biotransformation 335
Bleomycin 484
Bone marrow transplantation 361
Brain 1
Breast cancer 79, 367, 409, 451
Busulfan 226

Carboplatin 229, 239, 409, 481, 484
Carboplatin-based chemotherapy 234
Carboplatin/etoposide 389
Carcinoma of the cervix 52
Celiptium-induced nephrotoxicity 178
Cell-cycle progression 464
Cell density 417
Cell differentiation 171
Cell kinetics 121
Cellular pharmacokinetics 320, 417
Cerebellar toxicity 76
Cervical carcinoma 484
Chemotherapy 52, 72, 94, 385, 394, 413, 477
Children 60, 164, 397
2-Chloro-2′,3′-dideoxyadenose 285
Cimetidine 125
cis-Dichloro-*bis*-isopropylamine platinum (II) 248
Cisplatin 33, 52, 55, 111, 121, 131, 135, 211, 251, 347, 417, 464, 472
Cisplatin-resistant P388 leukemia 456
c-Myc expression 171
Combination chemotherapy 81, 131, 251
Combined modality treatment 94
Comparative disposition 106
Comparative effects 47
Cross-resistance 456
Cyclophosphamide 1, 125, 440
Cytarabine 33, 60, 76, 151
Cytosine arabinoside 141
Cytotoxicity 41, 342, 440

Dacarbine 81
Decarbazine pharmacokinetics 157
1,2-diaminocyclohexaneplatinum(IV) 335
Difluorodeoxycytidine 2′ 258
Distribution 347
DNA binding 248
DNA polymerase 199
Doxorubicin 47, 219
Doxorubicinol 219
Drug interaction 101
Drug resistance 151

Ecomustine 295
ELISA 115
Endocrinology 367
Epidoxorubicin 4′ 47
Epipodophyllotoxin 194
Epirubicin glucuronide 147
Etoposide 115

Feasibility 490
Flavone acetic acid 27
Flow-through system 320
Fluorouracil 5- 79, 131, 320, 477
Flutamide 401
Fotemustine 81
Fotemustine [^{14}]- 106

Galactosidase 115
Gastrointestinal lymphoma 385
Gemcitabine 258
Glioma 278

Head and neck carcinoma 464
Hepatic enzyme 226
Hepatocytes 320
Hepatoma BEL-7402 cells 41
High-dose cisplatin 243
High-dose epirubicin 394
High-grade glioma 481
Histidine 271